Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer

Abstract

ObjectivesTo apply a systems pathology-based approach to the quantification of nuclear Active β-catenin and human leukocyte antigen class I, and assess the biomarker involvement in a cohort of prostate tumor patients.ResultsThe systems pathology approach applied allows a precise quantification of the marker expression in the different cell compartments as well as the determination of the areas that coexpress two markers. Our data shows that the accumulation of β-catenin in the nuclear compartment is significantly decreased in the adjacent normal areas when compared to tumor of the same patients (p < 0.001). In conclusion, the application of this novel multiple immunofluorescence assay demonstrates that the upregulation of Active β-catenin is a relatively common feature of prostate tumor development, and further supports the activation of the Wnt/β-catenin pathway in prostate cancer progression.Electronic supplementary materialThe online version of this article (10.1186/s13104-019-4100-z) contains supplementary material, which is available to authorized users.

Multiplexed Opto-Microfluidic Biosensing: Advanced Platform for Prostate Cancer Detection

“…Traditional clinical methodologies for detecting PCa biomarkers present several significant limitations including high costs, complexity, patient discomfort, and lengthy analysis times. These conventional clinical assessments primarily rely on the PSA blood test and biopsy, enabling techniques such as immunohistochemistry (IHC), − immunofluorescence (IF), − specific protein quantification through Western blotting, − ELISA, − and reverse transcription-polymerase chain reaction. − …”